Ngoi, Natalie Y. L. http://orcid.org/0000-0003-2071-0715
PiliƩ, Patrick G.
McGrail, Daniel J.
Zimmermann, Michal http://orcid.org/0000-0002-9955-1675
Schlacher, Katharina
Yap, Timothy A. http://orcid.org/0000-0002-2154-3309
Article History
Accepted: 22 January 2024
First Online: 20 February 2024
Competing interests
: P.G.P. and D.J.M. are involved in a pending patent related to a replication stress response deficiency signature. M.Z. is an employee of Repare Therapeutics. T.A.Y. is Vice President and Head of Clinical Development in the Therapeutics Discovery Division at University of Texas MD Anderson Cancer Center, which has a commercial interest in DDR and other inhibitors; receives institutional research support funded by Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GSK, Genentech, Haihe, Ideaya, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, Vivace and Zenith; is a consultant for AbbVie, AstraZeneca, Acrivon, Adagene, Aduro, Almac, Amphista, Artios, Athena, Atrin, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, Boxer, BMS, C4 Therapeutics, Calithera, Cancer Res. UK, Clovis, Cybrexa, Diffusion, EMD Serono, F-Star, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Idience, Ignyta, I-Mab, ImmuneSensor, Impact, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI Pharma, Mereo, Merck, Natera, Nexys, Novocure, OHSU, OncoSec, Ono Pharma, Pegascy, PER, Pfizer, Piper Sandler, Prolynx, Repare, resTORbio, Roche, Schrodinger, Theragnostics, Varian, Versant, Vibliome, Xinthera, Zai Labs and ZielBio; and holds stock from Seagen. N.Y.L.N. and K.S. declare no competing interests.